drugset / Trial / NCT03344172
Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer
Phase 2
Terminated
32 enrolled
Nathan Bahary, MD
National Cancer Institute (NCI) · collabPfizer · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized phase II trial that will examine the ability of Avelumab to improve the clinical activity of a pre-operative regimen of gemcitabine, nab-paclitaxel and hydroxychloroquine in subjects with potentially resectable adenocarcinoma of the pancreas.
Timeline
- Start
- 2017-12-13
- Primary completion
- 2019-04-30
- Completion
- 2019-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | 10 mg/kg | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Background | Hydroxychloroquine | Small molecule | 600 mg | Oral |
| Background | Paclitaxel | Small molecule | 125 mg/m2 | — |